Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus PLAQUENIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus PLAQUENIL.
Hydroxychloroquine vs PLAQUENIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
Antimalarial and immunosuppressant; inhibits heme polymerase in Plasmodium, preventing conversion of toxic heme to hemozoin; also inhibits lysosomal function, antigen presentation, and cytokine production (e.g., IL-1, TNF-alpha) in autoimmune diseases.
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
400 mg (310 mg base) orally daily, or 400 mg/day in divided doses; maintenance: 200-400 mg/day
None Documented
None Documented
Clinical Note
moderateHydroxychloroquine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine."
Clinical Note
moderateHydroxychloroquine + Artemether
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
Clinical Note
moderateHydroxychloroquine + Chloroquine
"The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
Clinical Note
moderateTerminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Terminal elimination half-life: 32-50 days (range 22-124 days) due to extensive tissue distribution and slow release from melanin-rich tissues; requires long-term dosing to achieve steady state (3-6 months).
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Renal (50-70% unchanged), fecal (20-30% as metabolites), minor biliary.
Category A/B
Category C
Antimalarial / DMARD
Antimalarial
Hydroxychloroquine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."